Matches in SemOpenAlex for { <https://semopenalex.org/work/W2248993822> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2248993822 endingPage "1035" @default.
- W2248993822 startingPage "1035" @default.
- W2248993822 abstract "1035 Background: The EGF30008 trial assessed the efficacy of the combination of the anti-HER2 tyrosine kinase inhibitor LAP and the aromatase inhibitor (LET) compared with LET plus placebo in postmenopausal women with HER2+ and HR+ MBC. The TAnDEM study evaluated the benefits of adding TZ to the AI ANA in postmenopausal women with advanced HER2+ and HR+ MBC. Both studies demonstrated statistically significant improvements in progression-free survival (PFS) with the addition of anti-HER2 therapy. Methods: An economic model was used to evaluate the incremental cost per quality-adjusted life year (QALY) gained with LET+LAP versus ANA+TZ as first-line treatment in postmenopausal women with HR+ and HER2+ MBC from the U.K. NHS perspective. Expected PFS and overall survival (OS) with LET+LAP and ANA+TZ were based on adjusted indirect comparison using data from the TAnDEM and EGF30008 trials as well as the P025 trial of LET versus tamoxifen (TAM) and the TARGET and North American trials of ANA versus TAM. Costs and utility values were obtained from the literature. Results: Shown in the Table (all results are discounted). LET+LAP yields more progression-free life years (PFLYs), life years (LYs), and QALYs than ANA+TZ. Medication costs are greater with LET+LAP, partly due to longer PFS. These higher costs are offset by savings in costs of drug administration. LAP+LET is therefore dominant (less costly and more QALYs) versus ANA+TZ. Conclusions: Letrozole plus lapatinib has greater effectiveness and lower cost from the U.K. NHS perspective when indirectly compared with anastrozole plus trastuzumab. Measure LET+LAP ANA+TZ Difference Effectiveness PFLY 1.181 1.042 0.139 LY 3.399 3.021 0.378 QALYs 2.434 2.162 0.272 Costs (in £) Medication 29,568 21,031 8,537 Drug administration 520 13,753 -13,232 Other preprogression 8,285 7,307 978 Other postprogression 20,105 17,943 2,162 Total 58,479 60,033 -1,554 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline, Royal Marsden NHS Foundation Trust & Institute of Cancer Research Research Fund" @default.
- W2248993822 created "2016-06-24" @default.
- W2248993822 creator A5006240593 @default.
- W2248993822 creator A5012008169 @default.
- W2248993822 creator A5018450143 @default.
- W2248993822 creator A5043807580 @default.
- W2248993822 creator A5072230576 @default.
- W2248993822 creator A5077816696 @default.
- W2248993822 date "2010-05-20" @default.
- W2248993822 modified "2023-09-23" @default.
- W2248993822 title "Indirect comparison of the cost-effectiveness of letrozole plus lapatinib (LET+LAP) versus anastrozole plus trastuzumab (ANA+TZ) as first-line treatment for postmenopausal women with HER2+ and HR+ metastatic breast cancer (MBC) from the U.K. National Health Service (NHS) perspective." @default.
- W2248993822 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.1035" @default.
- W2248993822 hasPublicationYear "2010" @default.
- W2248993822 type Work @default.
- W2248993822 sameAs 2248993822 @default.
- W2248993822 citedByCount "3" @default.
- W2248993822 crossrefType "journal-article" @default.
- W2248993822 hasAuthorship W2248993822A5006240593 @default.
- W2248993822 hasAuthorship W2248993822A5012008169 @default.
- W2248993822 hasAuthorship W2248993822A5018450143 @default.
- W2248993822 hasAuthorship W2248993822A5043807580 @default.
- W2248993822 hasAuthorship W2248993822A5072230576 @default.
- W2248993822 hasAuthorship W2248993822A5077816696 @default.
- W2248993822 hasConcept C112930515 @default.
- W2248993822 hasConcept C121608353 @default.
- W2248993822 hasConcept C126322002 @default.
- W2248993822 hasConcept C143998085 @default.
- W2248993822 hasConcept C2775930923 @default.
- W2248993822 hasConcept C2776215463 @default.
- W2248993822 hasConcept C2776694085 @default.
- W2248993822 hasConcept C2777176818 @default.
- W2248993822 hasConcept C2777329042 @default.
- W2248993822 hasConcept C2778812593 @default.
- W2248993822 hasConcept C2779786085 @default.
- W2248993822 hasConcept C2780739268 @default.
- W2248993822 hasConcept C29456083 @default.
- W2248993822 hasConcept C3019080777 @default.
- W2248993822 hasConcept C530470458 @default.
- W2248993822 hasConcept C71924100 @default.
- W2248993822 hasConceptScore W2248993822C112930515 @default.
- W2248993822 hasConceptScore W2248993822C121608353 @default.
- W2248993822 hasConceptScore W2248993822C126322002 @default.
- W2248993822 hasConceptScore W2248993822C143998085 @default.
- W2248993822 hasConceptScore W2248993822C2775930923 @default.
- W2248993822 hasConceptScore W2248993822C2776215463 @default.
- W2248993822 hasConceptScore W2248993822C2776694085 @default.
- W2248993822 hasConceptScore W2248993822C2777176818 @default.
- W2248993822 hasConceptScore W2248993822C2777329042 @default.
- W2248993822 hasConceptScore W2248993822C2778812593 @default.
- W2248993822 hasConceptScore W2248993822C2779786085 @default.
- W2248993822 hasConceptScore W2248993822C2780739268 @default.
- W2248993822 hasConceptScore W2248993822C29456083 @default.
- W2248993822 hasConceptScore W2248993822C3019080777 @default.
- W2248993822 hasConceptScore W2248993822C530470458 @default.
- W2248993822 hasConceptScore W2248993822C71924100 @default.
- W2248993822 hasIssue "15_suppl" @default.
- W2248993822 hasLocation W22489938221 @default.
- W2248993822 hasOpenAccess W2248993822 @default.
- W2248993822 hasPrimaryLocation W22489938221 @default.
- W2248993822 hasRelatedWork W2005023393 @default.
- W2248993822 hasRelatedWork W2052127963 @default.
- W2248993822 hasRelatedWork W2070897543 @default.
- W2248993822 hasRelatedWork W2081876561 @default.
- W2248993822 hasRelatedWork W2105859598 @default.
- W2248993822 hasRelatedWork W2162455270 @default.
- W2248993822 hasRelatedWork W2248993822 @default.
- W2248993822 hasRelatedWork W2793093901 @default.
- W2248993822 hasRelatedWork W4237582555 @default.
- W2248993822 hasRelatedWork W4242106749 @default.
- W2248993822 hasVolume "28" @default.
- W2248993822 isParatext "false" @default.
- W2248993822 isRetracted "false" @default.
- W2248993822 magId "2248993822" @default.
- W2248993822 workType "article" @default.